Crinetics Pharmaceuticals (CRNX) Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CRNX Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$83.62 |
| 52 Week High | US$83.63 |
| 52 Week Low | US$25.83 |
| Beta | 0.23 |
| 1 Month Change | 139.12% |
| 3 Month Change | 112.02% |
| 1 Year Change | 161.39% |
| 3 Year Change | 308.30% |
| 5 Year Change | 324.25% |
| Change since IPO | 241.17% |
Recent News & Updates
Recent updates
Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know
Summary Vertex Pharmaceuticals Incorporated acquires Crinetics Pharmaceuticals, Inc. for $85/share, valuing the deal at ~$10bn to diversify beyond its cystic fibrosis franchise. CRNX brings PALSONIFY, a newly approved oral acromegaly therapy with blockbuster potential, and atumelnant, a Phase 3 CAH candidate, strengthening VRTX's rare disease portfolio. VRTX expects Crinetics' assets to deliver up to $5bn peak annual revenues, supporting a path toward five blockbuster products and ~$20bn revenues by 2030. The CRNX acquisition is funded by cash and debt, leveraging VRTX's strong balance sheet, with anticipated deal closure in Q3 2026 and minimal near-term financial strain. Read the full article on Seeking Alpha
CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking AlphaCrinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking AlphaCrinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking AlphaShareholder Returns
| CRNX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 98.0% | 2.4% | -0.4% |
| 1Y | 161.4% | 47.2% | 18.4% |
Return vs Industry: CRNX exceeded the US Pharmaceuticals industry which returned 47.2% over the past year.
Return vs Market: CRNX exceeded the US Market which returned 18.4% over the past year.
Price Volatility
| CRNX volatility | |
|---|---|
| CRNX Average Weekly Movement | 29.2% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRNX's weekly volatility has increased from 16% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 594 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
| CRNX fundamental statistics | |
|---|---|
| Market cap | US$8.80b |
| Earnings (TTM) | -US$496.39m |
| Revenue (TTM) | US$18.07m |
Is CRNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNX income statement (TTM) | |
|---|---|
| Revenue | US$18.07m |
| Cost of Revenue | US$357.18m |
| Gross Profit | -US$339.11m |
| Other Expenses | US$157.28m |
| Earnings | -US$496.39m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 04, 2026
| Earnings per share (EPS) | -4.71 |
| Gross Margin | -1,876.73% |
| Net Profit Margin | -2,747.18% |
| Debt/Equity Ratio | 0% |
How did CRNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 21:43 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Crinetics Pharmaceuticals, Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |